Niranjan S. Rao
Lawrenceville, Jersey
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 3 publications
Oral spleen tyrosine kinase/Janus Kinase inhibitor gusacitinib for the treatment of chronic hand eczema: Results of a randomized phase 2 study.
Journal: Journal of the American Academy of Dermatology
Published: June 13, 2022
ASN004, A 5T4-targeting scFv-Fc Antibody-Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models.
Journal: Molecular cancer therapeutics
Published: November 24, 2020
Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis.
Journal: The Journal of allergy and clinical immunology
Published: April 02, 2019
Showing 1-3 of 3
Last Updated: 09/26/2026